100 British parliamentarians for ICC referral for Myanmar’s military general

Quader seeks India's cooperation for Rohingya repatriation

Tobacco farmers take over govt lands in Cox’s Bazar

PM urges all to use proper Bangla language

Nation pays glowing tributes to language martyrs

Nation pays glowing tributes to language martyrs

Health

16 November, 2017 09:06:43 AM

'Good' gut bacteria may solve Crohn's disease: study

Independent Online Desk

Researchers analyzed stool samples from 90 children with Crohn's disease, and compared them to 26 healthy children. AFP Photo

Fixing the balance of gut bacteria by introducing a specific kind of "good" bug could help treat Crohn's disease, a painful, inflammatory bowel condition that affects millions worldwide, researchers said Wednesday.

The cause is unknown, and there is no cure. Some patients seek surgery or use medicine or supplements to ease the symptoms, which can appear at random.

The report in the journal Science Translational Medicine calls for "wiping out a significant portion of the bacteria in the gut microbiome," with the help of antibiotics.

Then, bacteria that lacks a harmful enzyme known as urease, is introduced back into the gut so that symptoms can improve.

So far studies on mice and a small number of humans have shown promise in this approach, though more work is needed, study authors cautioned.

"Because it's a single enzyme that is involved in this process, it might be a targetable solution," said senior author, Gary Wu, associate chief for research in the division of Gastroenterology at the Perelman School of Medicine at the University of Pennsylvania.

"The idea would be that we could 'engineer' the composition of the microbiota in some way that lacks this particular one."

Researchers analyzed stool samples from 90 children with Crohn's disease, and compared them to 26 healthy children.

They found an abundance of proteobacteria in Crohn's patients.

This "bad" proteobacteria harbors the urease enzyme, which converts urea into ammonia, and fuels the intestinal imbalance in Crohn's disease, researchers said.

So they turned to lab mice to look for ways to combat it.

Previous research has shown that giving mice the antibiotics vancomycin and neomycin, along with an intestinal purging agent used before a colonoscopy "significantly reduced the bacterial load enough to create an opportunity for a newly introduced bacterial community to establish themselves," said the report.

So researchers tried this gut-purging approach in mice, and then introduced a single bacterial species, Escherichia coli.

If the E. coli was negative for the enzyme urease, the mice's gut health improved.

So far, researchers reported that five human subjects also underwent the antibiotic and colonoscopy-prep, and saw their intestinal bacterial load reduced 100,000-fold.

This suggests it "might be possible to engineer the composition of the gut microbiota in patients with inflammatory bowel disease," said the study.

A new study by Penn researchers in cooperation with the Children's Hospital of Philadelphia is under way to further examine this approach.

"Now that we can effectively reduce bacterial load in humans it may now be possible to engineer the microbiota into a different configuration in a manner similar to what we have achieved in mice," Wu said.

"Although we're closer now, there is still more work to be done."AFP.

KK

Good gut bacteria may solve Crohns disease: study

Independent Online Desk

Fixing the balance of gut bacteria by introducing a specific kind of good bug could help treat Crohns disease, a painful, inflammatory bowel condition that affects millions worldwide, researchers said Wednesday.
Symptoms of Crohns disease include frequent diarrhea, fever, cramping, fatigue, rectal bleeding and unexplained weight loss.
The cause is unknown, and there is no cure. Some patients seek surgery or use medicine or supplements to ease the symptoms, which can appear at random.
The report in the journal Science Translational Medicine calls for wiping out a significant portion of the bacteria in the gut microbiome, with the help of antibiotics.
Then, bacteria that lacks a harmful enzyme known as urease, is introduced back into the gut so that symptoms can improve.
So far studies on mice and a small number of humans have shown promise in this approach, though more work is needed, study authors cautioned.
Because its a single enzyme that is involved in this process, it might be a targetable solution, said senior author, Gary Wu, associate chief for research in the division of Gastroenterology at the Perelman School of Medicine at the University of Pennsylvania.
The idea would be that we could engineer the composition of the microbiota in some way that lacks this particular one.
Researchers analyzed stool samples from 90 children with Crohns disease, and compared them to 26 healthy children.
They found an abundance of proteobacteria in Crohns patients.
This bad proteobacteria harbors the urease enzyme, which converts urea into ammonia, and fuels the intestinal imbalance in Crohns disease, researchers said.
So they turned to lab mice to look for ways to combat it.
Previous research has shown that giving mice the antibiotics vancomycin and neomycin, along with an intestinal purging agent used before a colonoscopy significantly reduced the bacterial load enough to create an opportunity for a newly introduced bacterial community to establish themselves, said the report.
So researchers tried this gut-purging approach in mice, and then introduced a single bacterial species, Escherichia coli.
If the E. coli was negative for the enzyme urease, the mices gut health improved.
If the E. coli contained urease, mice experienced worsening intestinal inflammation and colitis.
So far, researchers reported that five human subjects also underwent the antibiotic and colonoscopy-prep, and saw their intestinal bacterial load reduced 100,000-fold.
This suggests it might be possible to engineer the composition of the gut microbiota in patients with inflammatory bowel disease, said the study.
A new study by Penn researchers in cooperation with the Childrens Hospital of Philadelphia is under way to further examine this approach.
Now that we can effectively reduce bacterial load in humans it may now be possible to engineer the microbiota into a different configuration in a manner similar to what we have achieved in mice, Wu said.
Although were closer now, there is still more work to be done.AFP.
KK

A precision cancer treatment that targets rare genetic mutations that exist in about 5,000 people in the United States instead of the tumor's location in the body has shown success in three-quarters of patients, researchers said…